Characterization of the response of dendritic cells and regulatory T cells to tumor antigens in patients with renal cell carcinoma

Chang Gung Medical Journal

Volumn 33, Issue 1, 2010, Pages 25-35

  Hou, Ming Mo ^a   Chang, John Wen Cheng ^a   Pang, See Tong ^a   Chiang, Yang Jen ^a   Shen, Yung Chi ^a   Liao, Shuen Kuei ^c   Hsieh, Jia Juan ^a   Yeh, Kun Yun ^b   Chang, Nai Jen ^a   Chuang, Cheng Keng ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Dendritic cells; Peripheral blood; Regulatory T cells; Renal cell carcinoma

Indexed keywords

ANTIGEN; B7 ANTIGEN; CD40 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; PROSTAGLANDIN E2; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; CELL ADHESION; CELL CULTURE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; MALE; MIXED LYMPHOCYTE REACTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR CELL DESTRUCTION;

ADULT; AGED; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CARCINOMA, RENAL CELL; DENDRITIC CELLS; FEMALE; HUMANS; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 77649221149     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Hart DN. Dendritic cells: unique leukocyte populations, which control the primary immune response. Blood 1997;90:3245-87.
2. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 1999;161:381-7.
3. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
4. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cell cancer: An outpatient multicenter trial. J Clin Oncol 1993;11:1809-16.
5. Wagner JR, Walther MM, Linehan WM, White DE, Rosenberg SA, Yang JC. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 1999;162:43-5.
6. Lummen G, Goepel M, Mollhoff S, Hinke A, Otto T, Rubben H. Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma. J Urol 1996;155:455-8.
7. Schreiber H. Tumor Immunology. In: Paul WE, ed. Fundamental Immunology. Raven, Philadelphia: Lippincott, 1999:1237-70.
8. Van den Eynde BJ, Van den Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997;9:684-93.
9. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997;8:1183-7.
10. Pardoll DM. Cancer vaccines. Nat Med 1997;4:525-31.
11. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-87.
12. + regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003;198:235-47.
13. Radhakrishnan S, Cabrera R, Schenk EL, Nava-Parada P, Bell MP, Van Keulen VP, Marker RJ, Felts SJ, Pease LR. Reprogrammed FoxP3+ T Regulatory Cells Become IL-17+ Antigen-Specific Autoimmune Effectors In Vitro and In Vivo. J Immunol 2008;181:3137-47.
14. Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL, Hawkins RE. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer immunol immunother 2007;56:1743-53.
15. + Regulatory T Cells, Which Suppress via Membrane-Bound TGFbeta-1. J Immunol 2008;181:2220-6.
16. 2-microglobulin genes. Cancer Immunol Immunother 2009;58:395-408.
17. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics. CA Cancer J Clin 1994;44:7-26.
18. DeKernion JB. Renal tumors. In: Walsh PC, Retik AB, Stamey TA, Vaughan Jr. ED, eds. Campbell's Urology, 6th ed. Philadelphia, PA: Saunders WB, 1993:1294-342.
19. Mulders P, Figlin R, deKernion JB, Wiltrout R, Linehan M, Parkinson D, deWolf W, Belldeqrun A. Renal cell carcinoma: recent progress and future directions. Cancer Res 1997;57:5189-95.
20. Golumbek P, Levitsky H, Jaffee L, Pardoll DM. The antitumor immune response as a problem of self-nonself discrimination; implications for immunotherapy. Immunol Rev 1993;12:183-92.
21. Maeurer MJ, Gollin SM, Martin D. Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996;98:1633-41.
22. Adams DH, Yannelli JR, Newman W. Adhesion of tumor-infiltrating lymphocytes to endothelium: a phenotypic and functional analysis. Br J Cancer 1997;75:1421-31.
23. Becker JC, Termeer C, Schmidt RE, Bröcker EB. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol 1997;151:7224-32.
24. Walker PR, Saas P, Dietrich P. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back. J Immunol 1997;158:4521-41.
25. Satthaporn S, Robins A, Vassanasiri W, El-Sheemy M, Jibril JA, Clark D, Valerio D, Eremin O. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 2004;53:510-8.
26. Hoffmann TK, Müller-Berghaus J, Ferris RL, Johnson JT, Storkus WJ, Whiteside TL. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 2002;8:1787-93.
27. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 1999;31:323-31.
28. Chang JW, Vaquerano JE, Zhou YM, Peng M, Leong SP. Characterization of dendritic cells generated from peripheral blood of patients with malignant melanoma. Anticancer Res 1999;19:1815-20.
29. Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eu J Immunol 1994;24:605-10.
30. Grabbe S, Bruvers S, Gallo RL, Knisely TL, Nazareno R, Granstein RD. Tumor antigen presentation by murine epidermal cells. J Immunol 1991;146:3656-61.
31. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997;186:1177-82.
32. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558-61.
33. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-7.
34. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479-83.
35. Albert ML, Sauter B, and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-9.
36. Chang JW, Peng M, Vaquerano JE, Zhou YM, Clinton RA, Hyun WC, Giedlin MA, Leong SP. Induction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies. Anticancer Res 2000;20:1329-36.
37. Shimizu J, Zou JP, Ikegame K, Katagiri T, Fujiwara H, Hamaoka T. Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts. J Immunol 1991;146:708-14.
38. Kahn HJ, Marks A, Thom H, Baumal R. Role of antibody to S100 protein in diagnostic pathology. Am J Clin Pathol 1983;79:341-7.
39. Zhou LJ, Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 1995;154:3821-35.
40. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM. Pivotal role of the B7; CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994;84:3261-82.
41. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998;4:585-93.
42. Fearnley DB, McLellan AD, Mannering SI, Hock BD, Hart DN. Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: implications for studies on antigen-presenting cell function and immunotherapy. Blood 1997;89:3708-16.
43. Schwaab T, Schned AR, Heaney JA, Cole BF, Atzpodien J, Wittke F, Ernstoff MS. In vivo description of dendritic cells in human renal cell carcinoma. J Urol 1999;162:567-73.
44. Nomori H, Watanabe S, Nakajima T, Shimosato Y, Kameya T. Histiocytes in nasopharyngeal carcinoma in relation to prognosis. Cancer 1986;57:100-5.
45. Luft T, Jefford M, Luetjens P, Toy T, Hochrein H, Masterman KA, Maliszewski C, Shortman K, Cebon J, Maraskovsky E. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DCs subsets. Blood 2002;100:1362-72.
46. Harizi H, Juzan M, Pitard V, Moreau JF, Gualde N. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 2002;168:2255-63.
47. + regulatory T cells in self-tolerance and autoimmune disease. Curr Top Microbiol Immuno 2006;305:51-66.
48. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6.
49. Dyall J, Latouche JB, Schnell S, Sadelain M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 2001;97:114-21.
50. Sato T, Terai M, Yasuda R, Watanabe R, Berd D, Mastrangelo MJ, Hasumi K. Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy. Cancer Immunol Immunother 2004;53:53-61.